Cognition Therapeutics reaches target enrollment in Phase 2 START Study.
ByAinvest
Thursday, Nov 13, 2025 7:38 am ET1min read
CGTX--
Cognition Therapeutics has reached the target enrollment of 540 participants in its Phase 2 'START' Study. The study assesses the safety and activity of zervimesine (CT1812) in patients with mild cognitive impairment or early Alzheimer's disease. Topline results are expected after 18 months of treatment. The company attributes the strong enrollment numbers to interest from patients and investigators.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet